Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1816488rdf:typepubmed:Citationlld:pubmed
pubmed-article:1816488lifeskim:mentionsumls-concept:C0036126lld:lifeskim
pubmed-article:1816488lifeskim:mentionsumls-concept:C0037993lld:lifeskim
pubmed-article:1816488lifeskim:mentionsumls-concept:C0596638lld:lifeskim
pubmed-article:1816488lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:1816488lifeskim:mentionsumls-concept:C0021745lld:lifeskim
pubmed-article:1816488lifeskim:mentionsumls-concept:C0805586lld:lifeskim
pubmed-article:1816488lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:1816488pubmed:issue5lld:pubmed
pubmed-article:1816488pubmed:dateCreated1992-6-30lld:pubmed
pubmed-article:1816488pubmed:abstractTextAlthough IFN-gamma has been shown to play an important role in protection against a systemic S. typhimurium challenge, the in vivo and in vitro production of this cytokine following S. typhimurium infection of the gastrointestinal tract has not been investigated. In this study, IFN-gamma production by gut-associated lymphoid tissue and spleen was investigated in mice following oral challenge with S. typhimurium. Cells obtained from the Peyer's patches (PP), mesenteric lymph nodes (MLN) and spleen (Sp) of mice orally challenged with S. typhimurium were assessed for levels of IFN-gamma mRNA after varying times following in vivo infection. RNA obtained from the above tissues was subjected to reverse transcription followed by PCR amplification using primers specific for murine IFN-gamma. Elevated levels of IFN-gamma mRNA were first detected in the PP at 6 h post-challenge. Elevated levels of IFN-gamma mRNA were then detected in the MLN at 24 h and in the spleen at 4 days post-challenge. These in vivo results were in agreement with the ability of these lymphoid tissues to produce IFN-gamma upon in vitro stimulation with killed S. typhimurium. Neutralization of endogenously produced IFN-gamma by administration of mAb to IFN-gamma completely abrogated resistance to an oral challenge of S. typhimurium. A significant difference in the percent mortality was observed between the antibody-treated and control groups. Evaluation of bacterial spread in the antibody treated group versus the control group at 4 days following oral challenge revealed higher numbers of bacteria in the spleen and liver of antibody treated mice. These results clearly show that IFN-gamma is rapidly produced by gut-associated lymphoid tissue and spleen following oral S. typhimurium infection, and that endogenous production of IFN-gamma is essential in host resistance to S. typhimurium.lld:pubmed
pubmed-article:1816488pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1816488pubmed:languageenglld:pubmed
pubmed-article:1816488pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1816488pubmed:citationSubsetIMlld:pubmed
pubmed-article:1816488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1816488pubmed:statusMEDLINElld:pubmed
pubmed-article:1816488pubmed:monthNovlld:pubmed
pubmed-article:1816488pubmed:issn0882-4010lld:pubmed
pubmed-article:1816488pubmed:authorpubmed-author:KlimpelG RGRlld:pubmed
pubmed-article:1816488pubmed:authorpubmed-author:NieselD WDWlld:pubmed
pubmed-article:1816488pubmed:authorpubmed-author:RamarathinamL...lld:pubmed
pubmed-article:1816488pubmed:authorpubmed-author:ShabanR ARAlld:pubmed
pubmed-article:1816488pubmed:issnTypePrintlld:pubmed
pubmed-article:1816488pubmed:volume11lld:pubmed
pubmed-article:1816488pubmed:ownerNLMlld:pubmed
pubmed-article:1816488pubmed:authorsCompleteYlld:pubmed
pubmed-article:1816488pubmed:pagination347-56lld:pubmed
pubmed-article:1816488pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:meshHeadingpubmed-meshheading:1816488-...lld:pubmed
pubmed-article:1816488pubmed:year1991lld:pubmed
pubmed-article:1816488pubmed:articleTitleInterferon gamma (IFN-gamma) production by gut-associated lymphoid tissue and spleen following oral Salmonella typhimurium challenge.lld:pubmed
pubmed-article:1816488pubmed:affiliationDepartment of Microbiology, University of Texas Medical Branch, Galveston.lld:pubmed
pubmed-article:1816488pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1816488pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1816488pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1816488lld:pubmed